Drug intelligence / Profile preview

D064 + D702

Development stage: Unknown
Lead developer: Chong Kun Dang Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

D064 + D702 is an investigational fixed-dose combination therapy under clinical development for the treatment of essential hypertension and diabetes. The combination consists of two distinct agents, referred to as D064 and D702, being evaluated together for their efficacy and safety in patients with high blood pressure (hypertension), diabetes, and circulation disorders. The therapy is currently in Phase 3 clinical trials sponsored by Chong Kun Dang Pharmaceutical. Detailed mechanisms of action or molecular targets for either component have not been disclosed publicly as of June 2025.

Beyond the preview

Go deeper on D064 + D702.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on D064 + D702.

Explore the full profile